TW201021852A - Releasable fusogenic lipids for nucleic acids delivery systems - Google Patents

Releasable fusogenic lipids for nucleic acids delivery systems Download PDF

Info

Publication number
TW201021852A
TW201021852A TW098138943A TW98138943A TW201021852A TW 201021852 A TW201021852 A TW 201021852A TW 098138943 A TW098138943 A TW 098138943A TW 98138943 A TW98138943 A TW 98138943A TW 201021852 A TW201021852 A TW 201021852A
Authority
TW
Taiwan
Prior art keywords
group
substituted
ch2ch2
alkyl
2nhc
Prior art date
Application number
TW098138943A
Other languages
English (en)
Chinese (zh)
Inventor
Hong Zhao
wei-li Yan
lian-jun Shi
Maksim Royzen
Dechun Wu
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of TW201021852A publication Critical patent/TW201021852A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
TW098138943A 2008-11-17 2009-11-17 Releasable fusogenic lipids for nucleic acids delivery systems TW201021852A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11537808P 2008-11-17 2008-11-17

Publications (1)

Publication Number Publication Date
TW201021852A true TW201021852A (en) 2010-06-16

Family

ID=42170408

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098138943A TW201021852A (en) 2008-11-17 2009-11-17 Releasable fusogenic lipids for nucleic acids delivery systems

Country Status (7)

Country Link
US (1) US20110223257A1 (enExample)
EP (1) EP2355799A4 (enExample)
JP (1) JP2012509273A (enExample)
CN (1) CN102215820A (enExample)
CA (1) CA2742846A1 (enExample)
TW (1) TW201021852A (enExample)
WO (1) WO2010057160A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
TW201021853A (en) * 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable cationic lipids for nucleic acids delivery systems
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
KR20190039347A (ko) * 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
JP5860874B2 (ja) 2010-06-22 2016-02-16 デエヌア・テラプーティックDnatherapeutics 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化invivo送達システム
ME03353B (me) * 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
WO2013086354A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US10358680B2 (en) * 2012-09-11 2019-07-23 Duke University Nano-plasmonic molecular probes for plasmonics coupling interference
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
ES2966631T3 (es) 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
CN106659796B (zh) * 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
TWI665192B (zh) 2014-05-28 2019-07-11 德商拜耳作物科學股份有限公司 製備二氫異唑衍生物之方法
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2017044983A1 (en) 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CN107951862B (zh) * 2016-10-17 2021-03-12 南京绿叶制药有限公司 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
AU2018250312C1 (en) 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
CN117105811B (zh) * 2017-11-06 2025-12-12 日东电工株式会社 用于递送生物活性分子的膜融合化合物
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
LU103379B1 (en) * 2024-09-09 2026-03-09 Re3B Therapeutics Ug I G Serum-Protein Coated Fusogenic Lipid Particles For Targeted Drug Delivery

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
AU733310C (en) * 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US7015349B2 (en) * 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
EP1664316B1 (en) * 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
EP1692107A4 (en) * 2003-12-10 2008-10-29 Nitromed Inc NITROGEN OXIDE-RELATED PYRUVATE COMPOUNDS, COMPOSITIONS AND USE METHOD
US20060051405A1 (en) * 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
EP1845944A4 (en) * 2005-02-08 2011-07-27 Id Biomedical Corp Of Quebec C O B As Glaxosmithkline Biolog North America PHARMACEUTICAL COMPOSITIONS
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086881A2 (en) * 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
JP2008533016A (ja) * 2005-03-07 2008-08-21 アイディー バイオメディカル コーポレイション オブ ケベック シー.オー.ビー. アズ グラクソスミスクライン バイオロジカルズ ノース アメリカ 薬学的リポソーム組成物
EP1996607A4 (en) * 2006-02-01 2009-06-24 Burnham Inst Medical Research LYMPH ADDRESS CODES FOR TUMORS AND PREMALARY LESIONS
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
HUE040417T2 (hu) * 2007-05-04 2019-03-28 Marina Biotech Inc Aminosavlipidek és alkalmazásuk

Also Published As

Publication number Publication date
WO2010057160A1 (en) 2010-05-20
US20110223257A1 (en) 2011-09-15
CN102215820A (zh) 2011-10-12
WO2010057160A9 (en) 2011-05-05
EP2355799A1 (en) 2011-08-17
JP2012509273A (ja) 2012-04-19
CA2742846A1 (en) 2010-05-20
EP2355799A4 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
TW201021852A (en) Releasable fusogenic lipids for nucleic acids delivery systems
CN104922676B (zh) 聚胺衍生物
TW201023914A (en) Releasable polymeric lipids for nucleic acids delivery system
TW201021853A (en) Releasable cationic lipids for nucleic acids delivery systems
TWI594767B (zh) 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
TW201019969A (en) Branched cationic lipids for nucleic acids delivery system
TW201004658A (en) Nanoparticle compositions for nucleic acids delivery system
KR101762466B1 (ko) 지질, 지질 조성물 및 이의 사용 방법
JP5464556B2 (ja) 新規の正イオン性脂質、それの製造方法、およびそれを含む伝達体
US20120264810A1 (en) Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
CN109563511A (zh) 用于递送信使rna的组合物和方法
CN102231951A (zh) 用于核酸传递系统的可释放的偶联物
JP6240570B2 (ja) 脂質粒子および核酸送達キャリア
JP2013245190A (ja) 脂質膜構造体にpH依存性カチオン性を付与する剤、それによりpH依存性カチオン性が付与された脂質膜構造体および脂質膜構造体の製造方法
WO2025200517A1 (zh) 一种用于核酸递送的脂质材料及其用途
US20250375534A1 (en) Complexes for delivery of nucleic acids
WO2025167726A1 (zh) 靶向载体、靶向药物及制备方法与应用
JP2018024699A (ja) 脂質粒子および核酸送達キャリア
JP2013247890A (ja) トロポニンtと結合するdna、これを用いた腫瘍組織における血管新生および/または脈管形成抑制剤ならびにこれを用いた細胞内へ目的物質が取り込まれることを促進する剤